Understanding Nicotine Addiction: Personalizing Therapy for Smoking Cessation.

Area of Science:

• Pharmacology
• Addiction Medicine
• Public Health

Background:

• Smoking cessation is a global health priority due to high morbidity and mortality.
• Nicotine addiction, driven by nicotinic acetylcholine receptors, complicates cessation efforts.
• Current first-line therapies (nicotine replacement therapy, varenicline, bupropion) face challenges including cost, side effects, and availability.

Purpose of the Study:

• To review cytisine as a potential alternative smoking cessation aid.
• To address the limitations of existing smoking cessation pharmacotherapies.
• To highlight cytisine's established use in Eastern and Central Europe.

Main Methods:

• Literature review focusing on cytisine's pharmacology and clinical efficacy.
• Analysis of existing smoking cessation therapies and their drawbacks.
• Exploration of cytisine as a complementary tool for healthcare providers.

Main Results:

• Cytisine is a partial agonist of nicotinic acetylcholine receptors.
• It has demonstrated efficacy in smoking cessation in various studies.
• Cytisine offers a potentially more accessible and affordable alternative.

Conclusions:

• Cytisine represents a promising alternative pharmacotherapy for smoking cessation.
• Addressing the limitations of current treatments is crucial for public health.
• Further research and wider adoption of cytisine could improve cessation rates globally.